Letermovir is a non-nucleoside CMV-specific antiviral that inhibits the CMV DNA terminase complex (pUL56 subunit), disrupting the replication of the virus. Unlike traditional antivirals like ganciclovir or foscarnet, Letermovir is associated with significantly lower toxicity, especially bone marrow suppression, making it particularly suitable for patients undergoing HSCT, who are already at risk for hematologic complications.
Since its FDA approval in 2017, Letermovir has demonstrated remarkable efficacy in clinical trials, reducing the incidence of CMV disease in high-risk patients. Its oral and intravenous formulations provide flexibility in administration, further enhancing its clinical utility.
Hydroxypropyl Betadex (HP-β-CD) plays a critical role in the formulation of Letermovir (Prevymis®) injection, enabling its effective and safe use in clinical settings. Its contributions are summarized as follows:
1. Enhancing Drug Solubility
Letermovir is poorly soluble in water, which poses challenges for injectable formulations. Hydroxypropyl Betadex acts as an inclusion complexing agent, encapsulating the hydrophobic Letermovir molecules within its hydrophobic cavity. This significantly improves the solubility of Letermovir in aqueous solutions, making the injectable form viable for clinical application.
2. Improving Drug Stability
Letermovir is sensitive to environmental factors such as light, heat, and humidity, which can lead to degradation. By forming inclusion complexes, Hydroxypropyl Betadex provides a protective shield for Letermovir molecules, enhancing their physical and chemical stability. This protection ensures a longer shelf life and better storage conditions for the injection.
3. Enhancing Tolerability
Hydroxypropyl Betadex is highly biocompatible and has minimal toxicity, making it ideal for use in formulations intended for immunocompromised patients. In Letermovir injections, it also reduces the potential for irritation at the injection site, improving patient comfort and treatment tolerability.
4. Increasing Bioavailability
By improving the solubility and stability of Letermovir, Hydroxypropyl Betadex indirectly enhances the drug’s bioavailability. This ensures efficient absorption and therapeutic action at lower doses, reducing the likelihood of side effects while maximizing efficacy.
5. Enabling Flexible Drug Delivery
The inclusion of Hydroxypropyl Betadex has facilitated the development of Letermovir in injectable form, complementing its oral formulation. This flexibility is particularly valuable for patients unable to take oral medications, such as those in critical care or post-surgery recovery, broadening the clinical application.
xadl@xadl.com
Phone:86-29-8786211
Website: https://www.delicydextrin.com/
You can contact us directly on WhatsApp by clicking on the plugin on the right side of the page.
BETADEX SULFOBUTYL ETHER SODIUM
CAS No.: 182410-00-0
Standard : CP/USP/EP
DMF No.: 034772
CAS No.: 128446-35-5
Standard:CP/USP/EP
DMF No.: 034773
